In the battle against metastatic prostate cancer, the removal of lymph node metastases using image-guided surgery may have a high clinical impact on outcomes. Researchers at the 2017 Annual Meeting of the Society of Nuclear Medicine and Molecular Imaging (SNMMI) demonstrated preclinically that...
Radiation Oncology
-
-
The American Society for Radiation Oncology (ASTRO) released a statement last week strongly opposing the extensive cuts to cancer research and Medicaid funding in the Fiscal Year 2018 budget released by the White House. The association said these substantial reductions in support for medical...
-
February 27, 2017 — ViewRay Inc. announced that the company received 510(k) clearance from the U.S.
-
In the featured article from the February 2017 issue of the Journal of Nuclear Medicine, researchers document the first-in-human application of a new imaging agent to help find prostate cancer in both early and advanced stages and plan treatment. The study indicates that the new agent — a...
-
Join Chris Toth, president, Oncology Systems Americas, for a look at Varian’s new product introductions and major initiatives highlighted at ASTRO this year:
News | Oncology Information Management Systems (OIMS) | June 21, 2017
June 21, 2017 — The Department of Human Oncology at the University of Wisconsin-Madison has entered into an...
News | Intensity Modulated Radiation Therapy (IMRT) | June 20, 2017
June 20, 2017 — Accuray Inc. announced that the University Cancer Institute of Toulouse Oncopole (IUCT Oncopole) in...
News | Image Guided Radiation Therapy (IGRT) | June 19, 2017
June 19, 2017 — The Henry Ford Cancer Institute is the first in Michigan – and first in the world – to offer...
A 77-year-old male with recurrent lymph node and pulmonary metastases detected by Ga-68 PSMA PET/CT but not by conventional imaging. Graphic courtesy of the Department of Nuclear Medicine, Royal North Shore Hospital, Sydney
News | Prostate Cancer | June 15, 2017
An estimated one in seven American men will be affected by...
IMAGE OF THE YEAR: Dual-labeled PSMA-inhibitors for the diagnosis and therapy of prostate cancer. Technology of dual-labeled PSMA-inhibitors for PET/CT imaging and fluorescence-guided intraoperative identification of metastases. This work might help to establish a new treatment regimen for more precise and sensitive pre-, intra- and post-therapeutic detection of prostate cancer.
Credit: Courtesy of A. Baranski, M. Schäfer, U. Bauder-Wüst, M. Roscher, J. Schmidt, E. Stenau, L. Maier-Hein, M. Eder, K. Kopka, German Cancer Research Center, Heidelberg, Germany; T. Simpfendörfer, B. Hadaschik, U. Haberkorn, Heidelberg University Hospital, Heidelberg, Germany; PET-image: Afshar-Oromieh et al., EJNMMI 2013; 40(4); STED-image: J. Matthias, German Cancer Research Center.
This study was supported by the VIP+ fund, Federal Ministry of Education & Research (BMBF), Germany.
Scientific Paper 531: “Preclinical evaluation of dual-labeled PSMA-inhibitors for the diagnosis and therapy of prostate cancer.” A. Baranski, M. Schäfer, U. Bauder-Wüst, M. Roscher, J. Schmidt, E. Stenau, L. Maier-Hein, M. Eder, K. Kopka, German Cancer Research Center (DKFZ), Heidelberg, Germany; T. Simpfendörfer, B. Hadaschik, U. Haberkorn, University Hospital, Heidelberg, Germany. Presented at SNMMI’s 64th Annual Meeting, June 10-14, 2017, Denver, Colo.
News | Prostate Cancer | June 15, 2017
In the battle against metastatic ...
Image courtesy of Elekta
News | Radiation Therapy | June 13, 2017
Radiation therapy (RT) using high-energy particles...
News | Radiation Oncology | June 12, 2017
The alliance will study the feasibility of using CRnR’s converging x-ray lens technology as an effective...
News | Stereotactic Body Radiation Therapy (SBRT) | June 12, 2017
The American Society for Radiation Oncology (ASTRO) issued a new clinical guideline for the use of...
Sponsored Content | Case Study | Radiation Therapy | June 08, 2017
Stereotactic body radiation therapy (SBRT) employs significantly higher per fraction radiation doses than...
News | Radiation Oncology | June 08, 2017
In an article published in the June 2017 issue of The Journal of Nuclear Medicine, researchers assert that exposure...
Feature | Radiation Therapy | June 07, 2017 | By Melinda Taschetta-Millane
According to the National Institutes of Health (NIH), precision-based medicine is an emerging approach for disease...
News | Radiation Therapy | May 31, 2017
May 31, 2017 — The American Society for Radiation Oncology (ASTRO) released a statement last week strongly opposing...
News | Radiation Therapy | May 30, 2017
May 30, 2017 — Patients who were implanted with the BioZorb 3-D bioabsorbable marker during their...
News | Interventional Radiology | May 25, 2017
May 25, 2017 —The Royal College of Radiologists (RCR) has published a new edition of its guidance on the application...
The ZD2-Gd probe, represented by the orange ball and green arrow, binds to the EDB-FN in the prostate cancer cells with high metastatic potential. This results in a strong MRI signal (upper right). Prostate cancer cells with low metastatic potential have no EDB-FN and so there is no MRI signal (lower right). Credit: Han, et al., Bioconjug Chem-Apr-2017
News | Prostate Cancer | May 24, 2017
May 24, 2017 — A research team funded by the National Institute of Biomedical Imaging and Bioengineering (NIBIB) has...
News | Image Guided Radiation Therapy (IGRT) | May 24, 2017
May 24, 2017 — The University Medical Centre (UMC) Utrecht in the Netherlands recently treated the first patient as...
News | Proton Therapy | May 23, 2017
May 23, 2017 — IBA announced that the first patient has been treated with pencil beam scanning (PBS) technology at...
News | Radiation Therapy | May 19, 2017
May 19, 2017 — Registration has opened for the 59th Annual Meeting of the American Society for Radiation Oncology (...
News | Radiation Therapy | May 17, 2017
May 17, 2017 — RAD Technology Medical Systems and MidMichigan Medical Center — Alpena broke ground the end of March...
